Related Experiment Videos
Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional
Nicolaas E Deutz1, Eric M Matheson2, Laura E Matarese3
1Center for Translational Research in Aging & Longevity, Department of Health & Kinesiology, Texas A&M University, 1700 Research Parkway, College Station, TX 77845, USA.
Background:
Hospitalized, malnourished older adults have a high risk of readmission and mortality.
Objective:
Evaluation of a high-protein oral nutritional supplement (HP-HMB) containing beta-hydroxy-beta-methylbutyrate on postdischarge outcomes of nonelective readmission and mortality in malnourished, hospitalized older adults.
Design:
Multicenter, randomized, placebo-controlled, double-blind trial.
Setting:
Inpatient and posthospital discharge.
Patients:
Older (≥65 years), malnourished (Subjective Global Assessment [SGA] class B or C) adults hospitalized for congestive heart failure, acute myocardial infarction, pneumonia, or chronic obstructive pulmonary disease.
Interventions:
Standard-of-care plus HP-HMB (n = 328) or a placebo supplement (n = 324), 2 servings/day.
Measurements:
Primary composite endpoint was 90-day postdischarge incidence of death or nonelective readmission. Other endpoints included 30- and 60-day postdischarge incidence of death or readmission, length of stay (LOS), SGA class, body weight, and activities of daily living (ADL).
Results:
The primary composite endpoint was similar between HP-HMB (26.8%) and placebo (31.1%). No between-group differences were observed for 90-day readmission rate, but 90-day mortality was significantly lower with HP-HMB relative to placebo (4.8% vs. 9.7%; relative risk 0.49, 95% confidence interval [CI], 0.27 to 0.90; p = 0.018). The number-needed-to-treat to prevent 1 death was 20.3 (95% CI: 10.9, 121.4). Compared with placebo, HP-HMB resulted in improved odds of better nutritional status (SGA class, OR, 2.04, 95% CI: 1.28, 3.25, p = 0.009) at day 90, and an increase in body weight at day 30 (p = 0.035). LOS and ADL were similar between treatments.
Limitations:
Limited generalizability; patients represent a selected hospitalized population.
Conclusions:
Although no effects were observed for the primary composite endpoint, compared with placebo HP-HMB decreased mortality and improved indices of nutritional status during the 90-day observation period.
Clinical Trial Registration:
www.ClinicalTrials.govNCT01626742.